Skip to Main Content

Paper Details

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib.
Breast Cancer Res Treat
60
2012
BRCA, BRCA mutation, BRCA1, CHEK2, MK2, MRE11A, NBS1, PARP, Poly(ADP-ribose), Poly(ADP-ribose) polymerase, TDG, U133A/plus, XPA, basal subtype tumors, breast cancer, breast cancer cell lines, cell lines, deficiency in homologous recombination, invasive breast cancer, olaparib, patients, resistant cell lines, seven-gene, seven-gene signature, tumors

Datasets

Release 1.2